About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 2

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS) Due to Benign Prostatic Hypertrophy (BPH)

NCT00427219•Spectrum Pharmaceuticals, Inc

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Benign Prostatic Hypertrophy

Interventions

Ozarelix

Placebo

Locations

13

United States

Locations (13)

Donald Gleason, MD

Tucson, Arizona, United States

Jay Young, MD

Laguna Hills, California, United States

Alexander Gershman, MD

Los Angeles, California, United States

Stephen Auerbach, MD

Newport Beach, California, United States

Eugene Dula, MD

Tarzana, California, United States

Joel Kaufman, MD

Aurora, Colorado, United States

Key Dates

Start Date

January 23, 2007

Primary Completion Date

February 27, 2008

Completion Date

February 27, 2008

Last Updated

October 15, 2021

Related Studies

Intradetrusor Onabotulinumtoxin A (Botox) at the Time of Transurethral Resection of the Prostate or Transurethral Waterjet Ablation of the Prostate for Mixed Lower Urinary Tract Symptoms

NCT07377929

Benign Prostatic Hypertrophy (BPH)Lower Urinary Track Symptoms

Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours

NCT02401581

Benign Prostatic Hypertrophy

Dutasteride After Failure of Finasteride In the Management of Symptomatic Prostatic Enlargement/Hypertrophy (BPE/H)

NCT00382356

Benign Prostatic Hypertrophy

COMPLETEDPhase 3

Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

NCT00670306

Benign Prostatic Hypertrophy

COMPLETEDPhase 3

Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

NCT00663858

Benign Prostatic Hypertrophy

Sponsors

Lead Sponsor

Spectrum Pharmaceuticals, Inc

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 15, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions